Coeptis Therapeutics Holdings, Inc. (COEPW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Coeptis Therapeutics Holdings, Inc. (COEPW) trades at $0.01. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapies. Market cap: $64,721, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for COEPW: COEPW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates COEPW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
COEPW: 1/1 perspectives are bearish.
Coeptis Therapeutics Holdings, Inc. (COEPW) Healthcare & Pipeline Overview
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company specializing in the development of cell therapy platforms and diagnostic tools for cancer treatment. Their focus on CD38-related cancers and strategic collaborations positions them in the competitive biotechnology landscape, targeting unmet needs in oncology.
What Is the Investment Thesis for COEPW?
Coeptis Therapeutics Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative cell therapy platforms, particularly CD38-GEAR-NK, offers potential for significant growth in the treatment of CD38-related cancers. Key value drivers include successful clinical trials, regulatory approvals, and commercialization of its lead products. The collaborations with Statera BioPharma and Vici Health Sciences provide diversification and potential revenue streams. However, the company's limited operating history, small size (4 employees), and negative profitability (-1948.8% profit margin) pose significant risks. The company's success hinges on navigating the complex regulatory landscape, securing funding for ongoing research and development, and successfully commercializing its products. Investors should carefully consider the potential for dilution and the competitive landscape before investing.
Based on FMP financials and quantitative analysis
COEPW Key Highlights
- Coeptis Therapeutics Holdings, Inc. operates with a small team of 4 employees, indicating a lean operational structure.
- The company's product portfolio includes CD38-GEAR-NK, a Vy-Gen drug product targeting CD38-related cancers.
- Coeptis has a collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease.
- The company's gross margin is 21.1%, reflecting the profitability of its product sales before operating expenses.
- Coeptis Therapeutics Holdings, Inc. was founded in 2017, making it a relatively young company in the biotechnology sector.
Who Are COEPW's Competitors?
COEPW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKTX Akari Therapeutics, Plc | $14.32 | -3.37% | $16.39M | 43 |
| NKGN NKGen Biotech, Inc. Common Stock | $0.06 | -8.33% | $7.18M | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | 3B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are COEPW's Key Strengths?
- Innovative cell therapy platforms for cancer treatment.
- Strategic collaborations with other companies.
- Focus on unmet medical needs in oncology.
- Proprietary diagnostic tool for predicting patient response to therapies.
What Are COEPW's Weaknesses?
- Limited operating history and small size.
- Negative profitability and reliance on external funding.
- Concentration on a few key products and therapeutic areas.
- High regulatory hurdles and clinical trial risks.
What Could Drive COEPW Stock Higher?
- Clinical trial results for CD38-GEAR-NK in CD38-related cancers.
- Regulatory approval decisions for CD38-Diagnostic.
- Progress in the development and commercialization of STAT-201 for Crohn's disease.
- Advancement of CPT60621 for the treatment of Parkinson's Disease.
What Are the Key Risks for COEPW?
- Clinical trial failures for CD38-GEAR-NK or STAT-201.
- Regulatory setbacks and delays in product approvals.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Reliance on external funding and potential for dilution.
- Intellectual property disputes and patent expirations.
What Are the Growth Opportunities for COEPW?
- CD38-GEAR-NK Development: The primary growth opportunity lies in the continued development and commercialization of CD38-GEAR-NK for the treatment of CD38-related cancers. The market for multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia is substantial, with increasing demand for novel therapies. Successful clinical trials and regulatory approval could drive significant revenue growth for Coeptis. The timeline for this growth opportunity depends on the speed of clinical trials and regulatory review processes, potentially leading to commercialization within the next 3-5 years.
- CD38-Diagnostic Commercialization: The commercialization of CD38-Diagnostic, an in vitro screening tool, represents another key growth opportunity. This diagnostic tool can help personalize treatment approaches and improve the efficacy of anti-CD38 therapies. The market for companion diagnostics is expanding, driven by the increasing focus on precision medicine. Successful adoption of CD38-Diagnostic by oncologists could generate revenue through diagnostic testing services and partnerships with pharmaceutical companies. The timeline for this growth opportunity is shorter, with potential for commercialization within the next 1-2 years.
- STAT-201 for Crohn's Disease: The collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease offers diversification and growth potential beyond oncology. The market for Crohn's disease therapies is substantial, with a growing need for effective treatments. Successful development and commercialization of STAT-201 could generate revenue through licensing agreements and product sales. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory approvals, potentially leading to commercialization within the next 3-5 years.
- CPT60621 for Parkinson's Disease: The co-development of CPT60621 with Vici Health Sciences, LLC for the treatment of Parkinson's Disease represents another diversification opportunity. The market for Parkinson's disease therapies is growing, driven by the aging population and increasing prevalence of the disease. Successful development and commercialization of CPT60621 could generate revenue through licensing agreements and product sales. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory approvals, potentially leading to commercialization within the next 5-7 years.
- Strategic Partnerships and Acquisitions: Coeptis can pursue strategic partnerships and acquisitions to expand its product pipeline, access new technologies, and accelerate growth. Collaborations with other biotechnology companies and research institutions can provide access to innovative therapies and diagnostic tools. Acquisitions of complementary businesses can expand Coeptis's market reach and product offerings. The timeline for this growth opportunity is variable, depending on the availability of suitable targets and the negotiation of favorable terms.
What Opportunities Does COEPW Have?
- Expansion of product pipeline through internal development and acquisitions.
- Commercialization of CD38-GEAR-NK and CD38-Diagnostic.
- Strategic partnerships with pharmaceutical companies.
- Entry into new therapeutic areas beyond oncology.
What Threats Does COEPW Face?
- Competition from established pharmaceutical companies and other biotechnology firms.
- Regulatory setbacks and clinical trial failures.
- Intellectual property disputes and patent expirations.
- Economic downturns and funding constraints.
What Are COEPW's Competitive Advantages?
- Proprietary cell therapy platforms for targeted cancer treatment.
- In vitro diagnostic tool for predicting patient response to therapies.
- Strategic collaborations with other companies to expand product pipeline.
- Focus on unmet medical needs in oncology and other therapeutic areas.
What Does COEPW Do?
Coeptis Therapeutics Holdings, Inc., founded in 2017 and headquartered in Wexford, Pennsylvania, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies and diagnostic tools for cancer patients. The company's core focus lies in cell therapy platforms and pharmaceutical products designed to address unmet needs in oncology. Coeptis's product portfolio includes CD38-GEAR-NK, a Vy-Gen drug product targeting CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. This therapy aims to improve outcomes for patients with these challenging hematological malignancies. Complementing this therapeutic offering is CD38-Diagnostic, an in vitro screening tool designed to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibody therapies. This diagnostic tool has the potential to personalize treatment approaches and enhance the efficacy of anti-CD38 therapies. Coeptis has established strategic collaborations to expand its pipeline and capabilities. A collaboration with Statera BioPharma focuses on developing and commercializing STAT-201 for Crohn's disease, while a partnership with Vici Health Sciences, LLC aims to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. These collaborations diversify Coeptis's therapeutic interests beyond oncology and into other areas of significant medical need.
What Products and Services Does COEPW Offer?
- Develops cell therapy platforms for cancer treatment.
- Commercializes generic and branded pharmaceutical products.
- Focuses on therapies for CD38-related cancers.
- Offers an in vitro screening tool to predict patient response to anti-CD38 therapies.
- Collaborates with other companies to expand its product pipeline.
- Aims to improve outcomes for patients with cancer and other diseases.
How Does COEPW Make Money?
- Develops and commercializes pharmaceutical products and cell therapy platforms.
- Generates revenue through product sales and licensing agreements.
- Collaborates with other companies to share development costs and ownership rights.
- Focuses on developing innovative therapies for unmet medical needs.
What Industry Does COEPW Operate In?
Coeptis Therapeutics Holdings, Inc. operates within the competitive biotechnology industry, which is characterized by rapid innovation, high regulatory hurdles, and significant capital requirements. The global biotechnology market is projected to reach billions of dollars by 2026, driven by advancements in genomics, proteomics, and cell therapy. Coeptis's focus on cancer therapeutics aligns with the growing demand for innovative oncology treatments. The company faces competition from established pharmaceutical companies and other emerging biotechnology firms, including Aktis Oncology (AKTX), which focuses on targeted cancer therapies. Success in this industry requires strong intellectual property, efficient clinical trial execution, and effective commercialization strategies.
Who Are COEPW's Key Customers?
- Cancer patients seeking innovative treatment options.
- Oncologists prescribing therapies for CD38-related cancers.
- Hospitals and clinics using diagnostic tools to personalize treatment.
- Pharmaceutical companies partnering for drug development and commercialization.
COEPW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in upcoming developments.
- Community sentiment has shifted positively as discussions around potential partnerships and product pipelines have gained traction.
- Market perception is buoyed by recent advancements in their therapeutic offerings, which could address unmet medical needs.
- The overall biotech sector has seen increased interest, and COEPW could benefit from this broader market enthusiasm.
Bear Case
- Concerns linger about the company's ability to execute its clinical trials on schedule, which could impact investor confidence.
- Social sentiment has shown volatility, with some community members expressing skepticism about the long-term viability of its products.
- Recent regulatory challenges in the biotech space have raised caution among investors, affecting overall sentiment towards COEPW.
- Market perception remains cautious due to the competitive landscape, where many firms are vying for similar therapeutic advancements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
COEPW Latest News
No recent news available for COEPW.
COEPW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COEPW.
Price Targets
Wall Street price target analysis for COEPW.
COEPW MoonshotScore
What does this score mean?
The MoonshotScore rates COEPW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Mehalick
Unknown
David Mehalick is the CEO of Coeptis Therapeutics Holdings, Inc. Information regarding his detailed background, career history, education, and previous roles is not available in the provided data. His leadership is crucial for guiding the company's strategic direction and overseeing the development and commercialization of its products.
Track Record: Information about David Mehalick's specific achievements, strategic decisions, and company milestones under his leadership is not available in the provided data. Assessing his track record is challenging due to the limited information available.
COEPW Healthcare Stock FAQ
What does Coeptis Therapeutics Holdings, Inc. do?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies and diagnostic tools for cancer patients. Their primary focus is on cell therapy platforms, particularly CD38-GEAR-NK, which targets CD38-related cancers like multiple myeloma and leukemia. They also offer CD38-Diagnostic, an in vitro screening tool designed to predict which patients will benefit most from anti-CD38 antibody therapies. Additionally, Coeptis collaborates with other companies to expand its pipeline into areas like Crohn's disease and Parkinson's disease.
What are the main risks for COEPW?
The main risks for Coeptis Therapeutics Holdings, Inc. include the inherent challenges of drug development, such as clinical trial failures and regulatory setbacks. The company's limited operating history and small size make it vulnerable to financial constraints and competition from larger, more established pharmaceutical companies. Reliance on external funding and strategic collaborations also pose risks, as these relationships can be subject to change. Additionally, intellectual property disputes and patent expirations could negatively impact the company's competitive position.
What are the key factors to evaluate for COEPW?
Evaluate COEPW on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does COEPW data refresh on this page?
COEPW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven COEPW's recent stock price performance?
Coeptis Therapeutics Holdings, Inc. (COEPW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative cell therapy platforms for cancer treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider COEPW overvalued or undervalued right now?
Valuing Coeptis Therapeutics Holdings, Inc. (COEPW) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying COEPW?
Before investing in Coeptis Therapeutics Holdings, Inc. (COEPW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding COEPW to a portfolio?
Key strength of Coeptis Therapeutics Holdings, Inc. (COEPW): Innovative cell therapy platforms for cancer treatment. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- AI analysis is pending and may provide further insights.
- Information on CEO's background and track record is limited.